Program

Designed for clinicians, scientists, and all other members of the cancer care and research community, the 2019 Gastrointestinal Cancers Symposium will feature a wide array of multidisciplinary topics and expert faculty will offer insights on the application of gastrointestinal advances in: cancers of the esophagus and stomach, pancreas, small bowel and hepatobiliary tract, and the colon, rectum and anus.

For trainee and early career attendees, we offer a chance to attend a Networking Luncheon, to discuss career planning and cultivating your own place in the medical community.  The meeting will also offer several other robust opportunities for networking, discussion, and face to face engagement with faculty members and other attendees.

6:30 AM-7:55 AM Complimentary Continental Breakfast
6:30 AM-6:30 PM Exhibits Open
7:00 AM-7:45 AM

Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Philip A. Philip, MD, PhD, FRCP—Chair
Karmanos Cancer Institute, Wayne State University

Shailesh V. Shrikhande, MD, MS, FRCS—Chair
Tata Memorial Hospital

Abstract 185: Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
First Author: Ahmed Omar Kaseb, MD

Question and Answer

Abstract 190: Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.
First Author: Jonathan R. Strosberg, MD

Question and Answer

Abstract 191: Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program.
First Author: Michael J. Pishvaian, MD, PhD

Question and Answer

Abstract 192: Immune checkpoint inhibition (ICI) in combination with SBRT in patients with advanced pancreatic adenocarcinoma (aPDAC).
First Author: Gagandeep Brar, MD

Question and Answer

7:00 AM-7:45 AM Breakout Session: Novel Innovations in Pancreatic and Hepatobiliary Malignancies

Ryan Fields, MD, FACS—Chair
Washington University School of Medicine in St. Louis

Maria Majella Doyle, MD, MBA
Washington University School of Medicine in St. Louis
Liver Directed Therapy for Primary Hepatic Malignancies

Yuman Fong, MD
City of Hope
Advances in Minimally Invasive Surgery

Panel Question and Answer
7:55 AM-9:30 AM Welcome and General Session 4: The Evolving Landscape of Neuroendocrine Tumors

Jennifer A. Chan, MD, MPH—Chair
Dana-Farber Cancer Institute

Parag Parikh, MD—Chair
Henry Ford Cancer Institute

Shishir K. Maithel, MD, FACS
Winship Cancer Institute, Emory University
Welcome of the Day

Arvind Dasari, MD, MS
The University of Texas MD Anderson Cancer Center
Classification and Evaluation of NETs to Guide Management Strategies

James R. Howe, MD
University of Iowa Carver College of Medicine
Surgical Management of Neuroendocrine Tumors

Erik Mittra, MD, PhD
Oregon Health and Science University
PRRT: Sequencing and Navigating the Treatment Armamentarium

Jennifer A. Chan, MD, MPH
Dana-Farber Cancer Institute
Current and Upcoming Clinical Trials

Panel Question and Answer
9:30 AM-10:00 AM Break
10:00 AM-11:30 AM General Session 5: Pancreatic Cancer—Real World Applications of the Data

Laura A. Dawson, MD—Chair
Princess Margaret Cancer Centre

Philip A. Philip, MD, PhD, FRCP—Chair
Karmanos Cancer Institute, Wayne State University

Peter Allen, MD, PhD
Duke University
Cystic Lesions: Early Diagnosis and Prevention of Cancer

Cristina Ferrone, MD
Massachusetts General Hospital
Sequencing Therapy for Resectable Pancreatic Cancer

Bassel F. El-Rayes, MD
Winship Cancer Institute, Emory University
Novel Strategies on the Horizon for Systemic Disease

Laura A. Dawson, MD
Princess Margaret Cancer Centre
Current and Upcoming Clinical Trials

Panel Question and Answer
11:30 AM-1:00 PM Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
With Complimentary Boxed Lunch
11:30 AM-1:00 PM Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
11:45 AM-12:45 PM Expert Advice and Guidance on Important Topics Networking Luncheon
You can view a full list of faculty, here.
1:00 PM-1:45 PM Keynote Lecture: The Fundamental Difference Between Palliative Treatment and Palliative Care

Shishir K. Maithel, MD, FACS—Chair
Winship Cancer Institute, Emory University

Kelly McMasters, MD, PhD
University of Louisville School of Medicine

Question and Answer
1:45 PM-2:00 PM Break
2:00 PM-3:30 PM

Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Flavio G. Rocha, MD—Chair
Virginia Mason Hospital and Medical Center

TBD—Chair

Abstract 186: Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).
First Author: Masatoshi Kudo, MD, PhD

Abstract 189: Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
First Author: Michiaki Unno, MD, PhD

Andrew X. Zhu, MD, PhD
Harvard Medical School, Massachusetts General Hospital Cancer Center
Discussion

Abstract 187: Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): a cohort of the ROAR basket trial.
First Author: Zev A. Wainberg, MD

Abstract 188: Integrative molecular profiling and response to chemotherapy on the COMPASS trial.
First Author: Grainne M. O'Kane, MB BCh BAO MRCPI, MD 

Heinz-Josef Lenz, MD
University of Southern California
Discussion

Panel Question and Answer

3:30 PM-4:00 PM Break
4:00 PM-5:30 PM General Session 6: Advancements in Treatment of Cholangiocarcinoma and Hepatocellular Carcinoma

Josep Llovet, MD, PhD—Chair
Icahn School of Medicine at Mount Sinai

Jinsil Seong, MD, PhD—Chair
Yonsei University College of Medicine

Rachna T. Shroff, MD
The University of Arizona Cancer Center
Novel Therapies for Cholangiocarcinoma: One Size Fits All?

Melinda Bachini
Cholangiocarcinoma Foundation
The Patient Perspective on Cancer Treatment

Bruno Sangro, MD, PhD
Clinica Universidad de Navarra and CIBEREHD
State of the Art Management of Advanced Hepatocellular Carcinoma

Josep Llovet, MD, PhD
Icahn School of Medicine at Mount Sinai
Current and Upcoming Clinical Trials

Panel Question and Answer
5:30 PM-6:30 PM Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
With Complimentary Wine and Cheese Reception
5:30 PM-6:30 PM Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
5:45 PM-6:30 PM

Poster Walks: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Laura A. Dawson, MD, FRCPC, FASTRO—Poster Walk Leader
Princess Margaret Cancer Centre

Abstract 236: Landscape of germline mutations in hepatobiliary carcinoma: Unrealized risk, untapped clinical trial opportunities.
First Author: Jewel Samadder, MD, MSc

Abstract 273: Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.
First Author: Michael Lee, FRACP, MBChB

Abstract 289: Landscape of circulating tumor DNA profiling of advanced pancreatic cancer (PDAC).
First Author: Kabir Mody, MD

Abstract 336: Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).
First Author: Charalampos S. Floudas, MD, DMSc, MS

Abstract 345: Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial.
First Author: Anne Demols, MD, PhD

 

Parag Parikh, MD—Poster Walk Leader
Henry Ford Cancer Institute

Abstract 298: Phase I study of nivolumab (Nivo) + nab-paclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC).
First Author: Zev A. Wainberg, MD

Abstract 332: Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509).
First Author: Jaume Capdevila, MD

Abstract 369: Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC).
First Author: Efrat Dotan, MD

Abstract 414: SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mfolfirinox versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.
First Author: Davendra Sohal, MD, MPH